Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Revenue: 2018-2025

Historic Revenue for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to -$110,000.

  • Cidara Therapeutics' Revenue fell 111.31% to -$110,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $12.3 million, marking a year-over-year decrease of 49.24%. This contributed to the annual value of $1.3 million for FY2024, which is 94.52% down from last year.
  • According to the latest figures from Q1 2025, Cidara Therapeutics' Revenue is -$110,000, which was down 136.42% from $302,000 recorded in Q2 2024.
  • In the past 5 years, Cidara Therapeutics' Revenue registered a high of $40.7 million during Q3 2022, and its lowest value of -$110,000 during Q1 2025.
  • Moreover, its 3-year median value for Revenue was $5.1 million (2023), whereas its average is $6.3 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 868.84% in 2021, then plummeted by 111.31% in 2025.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Revenue stood at $2.8 million in 2021, then spiked by 264.96% to $10.2 million in 2022, then climbed by 8.62% to $11.1 million in 2023, then plummeted by 94.07% to $302,000 in 2024, then slumped by 111.31% to -$110,000 in 2025.
  • Its last three reported values are -$110,000 in Q1 2025, $302,000 for Q2 2024, and $973,000 during Q1 2024.